Evidence map›Paper›PMID 35449633›Full record

ArticleCureus2022

Familial Essential Thrombocythemia With Novel MPL L502G and G208K Mutations.

Matthew Rendo, Christian Cavacece, Chung-Ting J Kou, Bradley W Beeler, Joshua Fenderson

Abstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Matthew RendoHematology and Oncology, Brooke Army Medical Center, San Antonio, USA.
Christian CavaceceInternal Medicine, Brooke Army Medical Center, San Antonio, USA.
Chung-Ting J KouHematology and Oncology, Brooke Army Medical Center, San Antonio, USA.
Bradley W BeelerHematology and Oncology, Brooke Army Medical Center, San Antonio, USA.
Joshua FendersonHematology and Oncology, Brooke Army Medical Center, San Antonio, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial essential thrombocythemia is characterized by the inheritance of germline mutations to progeny, thereby increasing the risk for the development of essential thrombocythemia. Here, we present two cases of young women who developed thromboembolic phenomena, one of whom with an ischemic event despite adequate anticoagulation. Through extended mutational testing, both were characterized as having novel mutations in the myeloproliferative leukemia virus (MPL) gene, and both individuals have fathers being treated for essential thrombocythemia. This case provides insight that in familial essential thrombocythemia, there remain uncharacterized mutations in this inherited conditional landscape.

Indexed as

essential thrombocythemiafamilial essential thrombocythemiainherited mpnjak2 negative essential thrombocythemiamplthromboembolism

Identifiers

PMID35449633
PMCPMC9012324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.